EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Diagnosis and Staging of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Biomarker-Directed Aptamer Panels

Mikkel B Kjær iD, Asger G Jørgensen iD, Søren Fjelstrup, Daniel M Dupont iD, Claus Bus iD, Peter L Eriksen iD, Karen L Thomsen iD, Jeyanthini Risikesan iD, Søren Nielsen iD, Charlotte W Wernberg iD, Mette M Lauridsen iD, Elisabetta Bugianesi iD und 3 weitere

Biomolecules · 2025

DOI: 10.3390/biom15020255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Mikkel B Kjær und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Foundation, Steno Diabetes Center, ODIN—Open Discovery Network Aarhus University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects one-third of adults globally. Despite efforts to develop non-invasive diagnostic tools, liver biopsy remains the gold standard for diagnosing metabolic dysfunction-associated steatohepatitis (MASH) and assessing fibrosis. This study investigated RNA aptamer panels, selected using APTASHAPE technology, for non-invasive MASLD diagnosis and fibrosis stratification. Aptamer panels were selected in a cohort of individuals with MASLD (development cohort, n = 77) and tested in separate cohorts: one with MASLD (test cohort, n = 57) and one assessed for bariatric surgery (bariatric cohort, n = 62). A panel distinguishing MASLD without steatohepatitis from MASH accurately stratified individuals in the developmentcohort (AUC = 0.83) but failed in the test and bariatric cohorts. It did, however, distinguish healthy controls from individuals with MASLD, achieving an AUC of 0.72 in the test cohort. A panel for fibrosis stratification differentiated F0 from F3–4 fibrosis in the development cohort (AUC = 0.68) but not in other cohorts. Mass spectrometry identified five plasma proteins as potential targets of the discriminative aptamers, with complement factor H suggested as a novel MASLD biomarker. In conclusion, APTASHAPE shows promise as a non-invasive tool for diagnosing and staging MASLD and identifying associated plasma biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aptamers, NucleotideFatty LiverNon-alcoholic Fatty Liver DiseaseHumansBiomarkersMaleFemaleMiddle AgedAdultLiver CirrhosisSELEX Aptamer Technique

Stichwörter der Autor:innen

aptamerbiomarkermetabolic dysfunction-associated steatohepatitismetabolic dysfunction-associated steatotic liver disease

Substanzen

BiomarkersAptamers, Nucleotide

Autor:innen und Institutionen

  • Department of Hepatology and Gastroenterology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.
  • Department of Clinical Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.
  • Steno Diabetes Center Aarhus, Aarhus University Hospital, Palle Juul-Jensens Boulevard 11, 8200 Aarhus N, Denmark.
  • Interdisciplinary Nanoscience Centre (iNANO), Department of Molecular Biology and Genetics, Aarhus University, Gustav Wieds Vej 14, 8000 Aarhus C, Denmark.
  • Department of Gastroenterology and Hepatology, University Hospital of Southern Denmark, 6700 Esbjerg, Denmark.
  • ATLAS Centre for Functional Genomics, University of Southern Denmark, 5230 Odense, Denmark.

ORCID-Profile: Mikkel B Kjær, Asger G Jørgensen, Daniel M Dupont, Claus Bus, Peter L Eriksen, Karen L Thomsen, Jeyanthini Risikesan, Søren Nielsen, Charlotte W Wernberg, Mette M Lauridsen, Elisabetta Bugianesi, Chiara Rosso, Henning Grønbæk, Jørgen Kjems

Förderung

  • Novo Nordisk Foundation
  • Steno Diabetes Center
  • ODIN—Open Discovery Network Aarhus University
  • Steno Diabetes Center Aarhus (SDCA)

Zitieren

APA

Kjær, M. B., Jørgensen, A. G., Fjelstrup, S., Dupont, D. M., Bus, C., Eriksen, P. L., Thomsen, K. L., Risikesan, J., Nielsen, S., Wernberg, C. W., Lauridsen, M. M., Bugianesi, E., Rosso, C., Grønbæk, H., & Kjems, J. (2025). Diagnosis and Staging of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Biomarker-Directed Aptamer Panels. Biomolecules. https://doi.org/10.3390/biom15020255

Vancouver

Kjær MB, Jørgensen AG, Fjelstrup S, Dupont DM, Bus C, Eriksen PL, et al. Diagnosis and Staging of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Biomarker-Directed Aptamer Panels. Biomolecules. 2025. doi:10.3390/biom15020255

BibTeX
@article{Kjr2025,
  author = {Kjær, Mikkel B and Jørgensen, Asger G and Fjelstrup, Søren and Dupont, Daniel M and Bus, Claus and Eriksen, Peter L and Thomsen, Karen L and Risikesan, Jeyanthini and Nielsen, Søren and Wernberg, Charlotte W and Lauridsen, Mette M and Bugianesi, Elisabetta and Rosso, Chiara and Grønbæk, Henning and Kjems, Jørgen},
  title = {Diagnosis and Staging of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Biomarker-Directed Aptamer Panels},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15020255}
}
Kostenlos starten →